Back to results
US 9,005,900 B2Granted
TLE3 as a marker for chemotherapy
AssigneeClarient Diagnostic Services, Inc.
InventorsBrian Z. Ring, Douglas T. Ross, Robert S. Seitz, Rodney A. Beck
Life of this patent
Estimating the term…
Abstract
Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
Claims30
A method of identifying a breast cancer that will respond favorably to a chemotherapy treatment that includes a taxane or taxane derivative, the method comprising:
- (a) performing immunohistochemical staining for TLE3 polypeptide on a cancer sample obtained from a breast cancer patient, wherein the breast cancer patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers;
- (b) detecting a percentage and/or intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample, wherein the detected percentage and/or intensity is higher than a reference;
- and
- (c) identifying the patient's breast cancer as one that will respond favorably to a chemotherapy treatment that includes a taxane or taxane derivative,
- wherein the step of performing immunohistochemical staining comprises contacting the cancer sample with an antibody that binds TLE3 polypeptide thereby forming a complex comprising the antibody and TLE3 polypeptide, and the step of detecting comprises detecting the complex in the cancer sample.
2 more elements
A method of identifying a breast cancer that will respond favorably to a chemotherapy treatment that includes a taxane or taxane derivative, the method comprising:
- (a) performing immunohistochemical staining for TLE3 polypeptide on a cancer sample obtained from a breast cancer patient, wherein the breast cancer patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers;
- (b) detecting a percentage and/or intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample, wherein the detected percentage and/or intensity is higher than a reference;
- and
- (c) identifying the patient's breast cancer as one that will respond favorably to a chemotherapy treatment that includes a taxane or taxane derivative,
- wherein the step of performing immunohistochemical staining comprises contacting the cancer sample with a primary antibody that binds TLE3 polypeptide and a labeled secondary antibody that binds the primary antibody thereby forming a complex comprising the primary antibody, secondary antibody and TLE3 polypeptide, and the step of detecting comprises detecting the complex in the cancer sample.
2 more elements
A method of predicting the likelihood that a breast cancer will respond to a chemotherapy treatment that includes a taxane or taxane derivative, the method comprising:
- (a) performing immunohistochemical staining for TLE3 polypeptide on a cancer sample obtained from a breast cancer patient, wherein the breast cancer patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers;
- (b) detecting a percentage and/or intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample, wherein the detected percentage and/or intensity is higher than a reference;
- and
- (c) predicting that the patient's breast cancer will likely respond to a chemotherapy treatment that includes a taxane or taxane derivative,
- wherein the step of performing immunohistochemical staining comprises contacting the cancer sample with an antibody that binds TLE3 polypeptide thereby forming a complex comprising the antibody and TLE3 polypeptide, and the step of detecting comprises detecting the complex in the cancer sample.
2 more elements
A method of predicting the likelihood that a breast cancer will respond to a chemotherapy treatment that includes a taxane or taxane derivative, the method comprising:
- (a) performing immunohistochemical staining for TLE3 polypeptide on a cancer sample obtained from a breast cancer patient, wherein the breast cancer patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers;
- (b) detecting a percentage and/or intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample, wherein the detected percentage and/or intensity is higher than a reference;
- and
- (c) predicting that the patient's breast cancer will likely respond to a chemotherapy treatment that includes a taxane or taxane derivative,
- wherein the step of performing immunohistochemical staining comprises contacting the cancer sample with a primary antibody that binds TLE3 polypeptide and a labeled secondary antibody that binds the primary antibody thereby forming a complex comprising the primary antibody, secondary antibody and TLE3 polypeptide, and the step of detecting comprises detecting the complex in the cancer sample.
2 more elements
A method of treating a breast, lung or ovarian cancer patient, the method comprising:
- (a) performing immunohistochemical staining for TLE3 polypeptide on a cancer sample obtained from a breast, lung or ovarian cancer patient;
- (b) detecting a percentage and/or intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample, wherein the detected percentage and/or intensity is higher than a reference;
- and
- (c) administering a chemotherapy treatment that includes a taxane or taxane derivative to the patient,
- wherein the step of performing immunohistochemical staining comprises contacting the cancer sample with an antibody that binds TLE3 polypeptide thereby forming a complex comprising the antibody and TLE3 polypeptide and the step of detecting comprises detecting the complex in the cancer sample.
2 more elements
A method of treating a breast, lung or ovarian cancer patient, the method comprising:
- (a) performing immunohistochemical staining for TLE3 polypeptide on a cancer sample obtained from a breast, lung or ovarian cancer patient;
- (b) detecting a percentage and/or intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample, wherein the detected percentage and/or intensity is higher than a reference;
- and
- (c) administering a chemotherapy treatment that includes a taxane or taxane derivative to the patient,
- wherein the step of performing immunohistochemical staining comprises contacting the cancer sample with a primary antibody that binds TLE3 polypeptide and a labeled secondary antibody that binds the primary antibody thereby forming a complex comprising the primary antibody, secondary antibody and TLE3 polypeptide;
- and the step of detecting comprises detecting the complex in the cancer sample.
3 more elements
Dependencies are inferred from the claim text.